NASDAQ · ZNTL
Healthcare · Biotechnology
$2.51
Down-$0.04 (-1.57%)
Updated Oct 9, 2026, 10:00 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZNTL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
ZNTL closed at $2.51 after 21 trading sessions, down 30.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $2.51 | $2.535 | $2.39 | $2.51 | 1.27M |
| Oct 7, 2026 | $2.63 | $2.68 | $2.54 | $2.55 | 820.08K |
| Oct 6, 2026 | $2.81 | $2.8199 | $2.65 | $2.67 | 827.9K |
| Oct 5, 2026 | $2.69 | $2.8399 | $2.63 | $2.78 | 2.99M |
| Oct 2, 2026 | $2.64 | $2.65 | $2.495 | $2.52 | 1.45M |
| Oct 1, 2026 | $2.74 | $2.78 | $2.58 | $2.605 | 1.9M |
| Sep 30, 2026 | $2.71 | $2.795 | $2.605 | $2.77 | 1.01M |
| Sep 29, 2026 | $2.62 | $2.81 | $2.57 | $2.715 | 4.78M |
| Sep 28, 2026 | $2.70 | $2.70 | $2.57 | $2.60 | 1.27M |
| Sep 25, 2026 | $2.75 | $2.77 | $2.65 | $2.70 | 1.07M |
| Sep 24, 2026 | $2.84 | $2.89 | $2.73 | $2.75 | 1.17M |
| Sep 23, 2026 | $3.07 | $3.09 | $2.78 | $2.87 | 1.45M |
| Sep 22, 2026 | $3.07 | $3.14 | $3.01 | $3.08 | 956.31K |
| Sep 21, 2026 | $3.15 | $3.15 | $2.995 | $3.03 | 675.64K |
| Sep 18, 2026 | $3.07 | $3.18 | $2.99 | $3.11 | 1.26M |
| Sep 17, 2026 | $3.18 | $3.215 | $3.02 | $3.08 | 1.09M |
| Sep 16, 2026 | $3.23 | $3.26 | $3.035 | $3.10 | 1.23M |
| Sep 15, 2026 | $3.51 | $3.51 | $3.12 | $3.13 | 1.4M |
| Sep 14, 2026 | $3.47 | $3.57 | $3.44 | $3.50 | 750.36K |
| Sep 11, 2026 | $3.63 | $3.67 | $3.465 | $3.51 | 787.86K |
| Sep 10, 2026 | $3.74 | $3.765 | $3.555 | $3.59 | 864.21K |
The latest Smart Investors Daily articles mentioning ZNTL.
Company
Market Activity
Research & News
ZNTL research
Company profile and research snapshot.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | William Blair | Outperform | — |
| Jul 23, 2026 | Rodman & Renshaw | Buy | — |
| Jul 17, 2026 | Mizuho | Outperform | — |
| Apr 10, 2026 | Guggenheim | Buy | — |
| Mar 27, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 5, 2026
Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares rose 4. 4% in pre-market trading after Leerink Partners assumed coverage of the biotechnology company with an Outperform rating and an $8 price target.
Benzinga · Oct 5, 2026
Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.
Benzinga · Sep 16, 2026
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Benzinga · Sep 16, 2026
William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZNTL.
